转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

Nature子刊：利用pNaKtide降低氧化应激或有助治疗尿毒症心肌病

2016-10-06 佚名 生物谷

尿毒症
关注

在一项新的研究中，来自美国马歇尔大学、托雷多大学和纽约医学院的研究人员针对最近发现的Na/K泵（sodium-potassium pump）的信号转导功能进一步开展研究，鉴定出这一发现的一项重要的应用，从而可能潜在地导致人们开发出治疗肾脏疾病患者的新疗法。相关研究结果于2016年10月4日在线发表在自然出版集团旗下的Scientific Reports期刊上，论文标题为“Attenuation o



在一项新的研究中，来自美国马歇尔大学、托雷多大学和纽约医学院的研究人员针对最近发现的Na/K泵（sodium-potassium pump）的信号转导功能进一步开展研究，鉴定出这一发现的一项重要的应用，从而可能潜在地导致人们开发出治疗肾脏疾病患者的新疗法。相关研究结果于2016年10月4日在线发表在自然出版集团旗下的Scientific Reports期刊上，论文标题为“Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic Cardiomyopathy”。

这项研究的发现提示着导入肽pNaKtide降低氧化应激（oxidant stress）能够缓解实验性尿毒症心肌病（uremic cardiomyopathy），即一种几乎总是伴随着晚期肾功能衰竭的心脏病。尽管在美国，需要透析或器官移植的晚期肾功能衰竭仅影响每1***中的大约1到2人，但是较为温和的慢性肾脏疾病是非常常见的（占成年人人群的25%），而且也似乎与增加的心血管疾病发病率和死亡率相关联。

论文通信作者、马歇尔大学琼-爱德华兹医学院（Joan C. Edwards School of Medicine）主任Joseph I. Shapiro博士说，“我们的数据明确地表明这种肽显著地阻止和逆转小鼠体内的实验性尿毒症心肌病产生。这些发现提示着我们可能为之前无法治疗的疾病开发出有效的疗法。我想强调一下，当前的这项研究明确地确定了Zijian Xie博士在二十世纪九十年代晚期发现的这种Na/K泵的信号转导功能是一种重要的治疗靶标。”

Zijian Xie博士是马歇尔大学交叉学科研究所主任和马歇尔大学琼-爱德华兹医学院生物医学科学教授。

Xie说，“作为一名基础研究科学家，我特别高兴地看到我们针对这种Na/K泵的信号转导功能的发现可能真正地影响人类健康和临床医学。毋庸讳言，针对这种新的治疗靶标开发一种有效的药物仍然有好长的路要走。然而，我们对这种新的机会仍然感到非常激动人心。”

原始出处

Jiang Liu, Jiang Tian, Muhammad Chaudhry, Kyle Maxwell, Yanling Yan, Xiaoliang Wang, Preeya T. Shah, Asad A. Khawaja, Rebecca Martin, Tylor J. Robinette, Adee El-Hamdani, Michael W. Dodrill, Komal Sodhi, Christopher A. Drummond, Steven T. Haller, David J. Kennedy, Nader G. Abraham, Zijian Xie & Joseph I. Shapiro.Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic Cardiomyopathy.Scientific Reports.2016


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881357, encodeId=8253188135e80, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 26 21:35:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656148, encodeId=56c4165614862, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Mar 14 02:35:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145873, encodeId=b9a11458e38a, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145872, encodeId=565c1458e235, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:20 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290393, encodeId=f33a1290393ab, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445131, encodeId=125a144513165, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622248, encodeId=c20c16222480f, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2017-08-26 zhaojie88

    #Nat#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1881357, encodeId=8253188135e80, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 26 21:35:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656148, encodeId=56c4165614862, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Mar 14 02:35:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145873, encodeId=b9a11458e38a, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145872, encodeId=565c1458e235, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:20 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290393, encodeId=f33a1290393ab, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445131, encodeId=125a144513165, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622248, encodeId=c20c16222480f, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2017-03-14 xfpan20

    #Akt#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1881357, encodeId=8253188135e80, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 26 21:35:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656148, encodeId=56c4165614862, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Mar 14 02:35:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145873, encodeId=b9a11458e38a, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145872, encodeId=565c1458e235, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:20 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290393, encodeId=f33a1290393ab, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445131, encodeId=125a144513165, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622248, encodeId=c20c16222480f, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-11 知难而进

    继续关注！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1881357, encodeId=8253188135e80, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 26 21:35:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656148, encodeId=56c4165614862, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Mar 14 02:35:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145873, encodeId=b9a11458e38a, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145872, encodeId=565c1458e235, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:20 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290393, encodeId=f33a1290393ab, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445131, encodeId=125a144513165, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622248, encodeId=c20c16222480f, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-11 知难而进

    谢谢分享！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1881357, encodeId=8253188135e80, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 26 21:35:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656148, encodeId=56c4165614862, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Mar 14 02:35:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145873, encodeId=b9a11458e38a, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145872, encodeId=565c1458e235, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:20 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290393, encodeId=f33a1290393ab, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445131, encodeId=125a144513165, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622248, encodeId=c20c16222480f, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-08 tcm99hq

    #尿毒症#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1881357, encodeId=8253188135e80, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 26 21:35:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656148, encodeId=56c4165614862, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Mar 14 02:35:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145873, encodeId=b9a11458e38a, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145872, encodeId=565c1458e235, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:20 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290393, encodeId=f33a1290393ab, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445131, encodeId=125a144513165, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622248, encodeId=c20c16222480f, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-08 医者仁心

    #应激#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1881357, encodeId=8253188135e80, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 26 21:35:00 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656148, encodeId=56c4165614862, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Tue Mar 14 02:35:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145873, encodeId=b9a11458e38a, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:26 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145872, encodeId=565c1458e235, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Oct 11 22:20:20 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290393, encodeId=f33a1290393ab, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445131, encodeId=125a144513165, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622248, encodeId=c20c16222480f, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 08 01:35:00 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-08 爆笑小医

    #肌病#

    0

相关资讯

人造纤维可“清理”血液尿毒症毒素

日本物质和材料研究机构日前发表一份公报称，其研究人员开发出一种人造纤维，能够吸附肾衰竭患者血液中所含的尿毒症毒素肌酐，这一成果将有助于开发便携式小型透析装置。该机构主任研究员荏原充宏率领的研究小组，将能够吸附肌酐的沸石混合到树脂中，制作出了一种极细的纤维，并将这种纤维制成无纺布。血清实验显示，只要约１６克纤维，就可以将体重６０公斤的人在１小时之内产生的肌酐全部吸附干净。肌酐是血液中的一种低分子尿毒

KIDNEY INT：较高的血清阴离子间隙与死亡率正相关

　　 　　近期一项国际肾脏的研究报告中表明：在肾病的早期，较高的血清阴离子间隙可能与死亡率呈正相关。 　　研究中，调研了《全国健康和营养调查》1999年至2004年的数据，共11,957患者，研究人员分析了阴离子间隙肾功能和死亡率之间的关系。运用传统方法对数据进行处理：用白蛋白对阴离子间隙进行调整，再参考反映其他电解质的全部阴离子间隙的来计算血清阴离子间隙。 　　对阴离子间隙升高相对于肾小球

“提高腹膜透析治疗质量国际高峰论坛”顺利召开

    3月22日～24日，由北京大学肾脏病研究所、我院肾脏内科和国际腹膜透析学会主办、人民医院和第三医院肾脏内科共同协办的“提高腹膜透析治疗质量国际高峰论坛”在北京金台饭店顺利召开。卫生部医政司司长王羽、北京市卫生局领导邓小虹、医政处副处长路明、我院院长刘玉村、副院长丁洁出席了开幕式并做重要讲话。     1.  

慢性肾炎：容易被忽略的“隐形杀手”

肾脏疾病是一类比较常见的疾病，在我国慢性肾脏病的总患病率为10.8%，约有1.3亿人患有此类疾病。而慢性肾炎（绝大多数是慢性肾小球肾炎）是其中最主要的一部分，大概占到了所有慢性肾脏疾病的30%~40%左右，约合4000万人。

ERA-EDTA 2014：依库珠单抗可改善非典型溶血尿毒症综合征患者肾功能

2014年5月31日至6月3日，荷兰阿姆斯特丹举行的第51届欧洲肾脏协会及透析移植协会（ERA-EDTA）大会上，法国南茜大学医院中心Fakhouri博士发布了一项报告，指出无论有无移植史，依库珠单抗（人源型抗C5单克隆抗体）均能在临床上明显改善血栓性微血管病和逆转成人非典型溶血尿毒症综合征（aHUS）肾损害。Fakhouri博士表示无论患者是否经肾移植，都可见其肾功能和血小板计数在临床意义上的显

HIFU在尿毒症继发性甲状旁腺功能亢进中的治疗

    最近开发的为破坏甲状旁腺腺瘤的非侵入性的高强度聚焦超声（HIFU）技术可能对慢性肾脏疾病继发的甲状旁腺功能亢进（SHP）患者的治疗也是有益的。我们使用这种方法进行了试验研究。       研究者对5位慢性血液透析患者合并有严重的继发性甲状旁腺功能亢进，分别接受1至3次高强度聚焦超声治疗。接受这种治疗的患者均至少有一个或两个肿大的甲状旁腺